StockData

TuHURA Biosciences vs Phio Pharmaceuticals

HURA and PHIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HURA and PHIO compare

TuHURA Biosciences is the larger company, worth 11 times as much as Phio Pharmaceuticals ($89.2M against $8.3M).

Phio Pharmaceuticals scores higher on the StockData Score (5 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHURAPHIO
Size and price
Market cap$89.2M$8.3M
Share price$1.40$0.717
Change, 1 year−31.7%−44.8%
Change, 5 years−99.9%−99.5%
Beta (5Y)1.98−0.31
Employees226
StockData Score
Total score05 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score04 (better)
Dividend score00
Valuation
P/B4.8×0.7× (better)
FCF yield−33.5% (better)−147%
Profitability
Return on equity−161%−114% (better)
Financial health
Debt / equity–0.00
Current ratio0.18–
Altman Z-score−3.21 (better)−16.15
Piotroski F-score2–
Dividends and buybacks
Buyback yield−22.6%–
Shareholder yield−22.6%0.00% (better)
Ownership
Held by institutions14.1%5.6%
Held by insiders4.9%10.9%
Insider net buying, 12 months–$135K
Short interest, % of float10.2%0.83%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.